Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 181

1.

Legends in urology.

Sesterhenn I, Mostofi FK.

Can J Urol. 2014 Jun;21(3):7256-8. No abstract available.

2.

Ultrasound-accelerated formalin fixation of tissue improves morphology, antigen and mRNA preservation.

Chu WS, Furusato B, Wong K, Sesterhenn IA, Mostofi FK, Wei MQ, Zhu Z, Abbondanzo SL, Liang Q.

Mod Pathol. 2005 Jun;18(6):850-63.

3.

Armed Forces Institute of Pathology in jeopardy--who should care?

Gorstein F, Mostofi FK.

Hum Pathol. 2003 Mar;34(3):203-5; discussion 205. No abstract available.

PMID:
12673552
4.

Complete embedding and close step-sectioning of radical prostatectomy specimens both increase detection of extra-prostatic extension, and correlate with increased disease-free survival by stage of prostate cancer patients.

Desai A, Wu H, Sun L, Sesterhenn IA, Mostofi FK, McLeod D, Amling C, Kusuda L, Lance R, Herring J, Foley J, Baldwin D, Bishoff JT, Soderdahl D, Moul JW.

Prostate Cancer Prostatic Dis. 2002;5(3):212-8.

5.

Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues.

Merseburger AS, Kuczyk MA, Serth J, Bokemeyer C, Young DY, Sun L, Connelly RR, McLeod DG, Mostofi FK, Srivastava SK, Stenzl A, Moul JW, Sesterhenn IA.

Oncol Rep. 2003 Jan-Feb;10(1):223-8.

PMID:
12469173
6.

Insulin-like growth factors and risk of benign prostatic hyperplasia.

Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Sesterhenn IA, Mostofi FK, Fraumeni JF Jr, Hsing AW.

Prostate. 2002 Jul 1;52(2):98-105.

PMID:
12111701
7.

Polymorphic CAG/CAA repeat length in the AIB1/SRC-3 gene and prostate cancer risk: a population-based case-control study.

Hsing AW, Chokkalingam AP, Gao YT, Wu G, Wang X, Deng J, Cheng J, Sesterhenn IA, Mostofi FK, Chiang T, Chen YL, Stanczyk FZ, Chang C.

Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):337-41.

8.

Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.

Hsing AW, Chen C, Chokkalingam AP, Gao YT, Dightman DA, Nguyen HT, Deng J, Cheng J, Sesterhenn IA, Mostofi FK, Stanczyk FZ, Reichardt JK.

Cancer Epidemiol Biomarkers Prev. 2001 Oct;10(10):1077-82.

9.

Vitamin D receptor gene polymorphisms, insulin-like growth factors, and prostate cancer risk: a population-based case-control study in China.

Chokkalingam AP, McGlynn KA, Gao YT, Pollak M, Deng J, Sesterhenn IA, Mostofi FK, Fraumeni JF Jr, Hsing AW.

Cancer Res. 2001 Jun 1;61(11):4333-6.

10.

Prostate cancer, benign prostatic hyperplasia and physical activity in Shanghai, China.

Lacey JV Jr, Deng J, Dosemeci M, Gao YT, Mostofi FK, Sesterhenn IA, Xie T, Hsing AW.

Int J Epidemiol. 2001 Apr;30(2):341-9.

PMID:
11369740
11.

Insulin-like growth factors and prostate cancer: a population-based case-control study in China.

Chokkalingam AP, Pollak M, Fillmore CM, Gao YT, Stanczyk FZ, Deng J, Sesterhenn IA, Mostofi FK, Fears TR, Madigan MP, Ziegler RG, Fraumeni JF Jr, Hsing AW.

Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):421-7.

12.

Body size and prostate cancer: a population-based case-control study in China.

Hsing AW, Deng J, Sesterhenn IA, Mostofi FK, Stanczyk FZ, Benichou J, Xie T, Gao YT.

Cancer Epidemiol Biomarkers Prev. 2000 Dec;9(12):1335-41.

13.
14.

PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer.

Srikantan V, Zou Z, Petrovics G, Xu L, Augustus M, Davis L, Livezey JR, Connell T, Sesterhenn IA, Yoshino K, Buzard GS, Mostofi FK, McLeod DG, Moul JW, Srivastava S.

Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12216-21.

15.

Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China.

Hsing AW, Gao YT, Wu G, Wang X, Deng J, Chen YL, Sesterhenn IA, Mostofi FK, Benichou J, Chang C.

Cancer Res. 2000 Sep 15;60(18):5111-6.

17.

p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy.

Stackhouse GB, Sesterhenn IA, Bauer JJ, Mostofi FK, Connelly RR, Srivastava SK, Moul JW.

J Urol. 1999 Dec;162(6):2040-5.

PMID:
10569564
18.

Smooth muscle hyperplasia of the testicular adnexa clinically mimicking neoplasia: clinicopathologic study of sixteen cases.

Barton JH, Davis CJ Jr, Sesterhenn IA, Mostofi FK.

Am J Surg Pathol. 1999 Aug;23(8):903-9.

PMID:
10435559
19.

The "WHO/ISUP Consensus Classification of Urothelial (Transitional Cell) Neoplasms": continued discussion.

Reuter VE, Epstein JI, Amin MB, Mostofi FK.

Hum Pathol. 1999 Jul;30(7):879-80. No abstract available.

PMID:
10414511
20.

Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients.

Moul JW, Connelly RR, Mooneyhan RM, Zhang W, Sesterhenn IA, Mostofi FK, McLeod DG.

J Urol. 1999 Aug;162(2):394-7.

PMID:
10411045
21.

Allelic loss on chromosome 6Q in primary prostate cancer.

Srikantan V, Sesterhenn IA, Davis L, Hankins GR, Avallone FA, Livezey JR, Connelly R, Mostofi FK, McLeod DG, Moul JW, Chandrasekharappa SC, Srivastava S.

Int J Cancer. 1999 Jun 21;84(3):331-5.

22.

[Histopathologic and biological prognostic factors of clinical stage I non-seminomatous germ cell tumors. Implications for risk-adjusted therapy].

Heidenreich A, Sesterhenn IA, Mostofi FK, Moul JW, Engelmann UH.

Urologe A. 1999 Mar;38(2):168-78. German.

PMID:
10231939
24.

Immunohistochemical expression of monoclonal antibody 43-9F in testicular germ cell tumours.

Heidenreich A, Sesterhenn IA, Mostofi FK, Moul JW.

Int J Androl. 1998 Oct;21(5):283-8.

PMID:
9805244
25.
26.

Updated concepts and treatment of carcinoma in situ.

Lamm D, Herr H, Jakse G, Kuroda M, Mostofi FK, Okajima E, Sakamoto A, Sesterhenn I, da Silva FC.

Urol Oncol. 1998 Jul-Oct;4(4-5):130-8. No abstract available.

PMID:
21227218
27.

The molecular characteristics of bladder cancer in young patients.

Linn JF, Sesterhenn I, Mostofi FK, Schoenberg M.

J Urol. 1998 May;159(5):1493-6.

PMID:
9554340
28.

[Clinical stage I mature teratoma of the testis--retroperitoneal lymphadenectomy or surveillance?].

Heidenreich A, Neubauer S, Mostofi FK, Sesterhenn IA, Moul JW, Engelmann UH.

Urologe A. 1997 Sep;36(5):440-4. German.

PMID:
9424796
30.

Observations on the early detection of prostate cancer from the American Cancer Society National Prostate Cancer Detection Project.

Mettlin CJ, Murphy GP, Babaian RJ, Chesley A, Kane RA, Littrup PJ, Mostofi FK, Ray PS, Somers WJ, Toi A.

Cancer. 1997 Nov 1;80(9):1814-7.

PMID:
9351554
31.

Immunohistochemical expression of Ki-67 to predict lymph node involvement in clinical stage I nonseminomatous germ cell tumors.

Heidenreich A, Schenkmann NS, Sesterhenn IA, Mostofi FK, McCarthy WF, Heidenreich B, Moul JW.

J Urol. 1997 Aug;158(2):620-5.

PMID:
9224380
32.

Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients.

Douglas TH, Morgan TO, McLeod DG, Moul JW, Murphy GP, Barren R 3rd, Sesterhenn IA, Mostofi FK.

Cancer. 1997 Jul 1;80(1):107-14.

PMID:
9210715
33.

Prostate-specific antigen-detected prostate cancer (stage T1c): an analysis of whole-mount prostatectomy specimens.

Douglas TH, McLeod DG, Mostofi FK, Mooneyhan R, Connelly R, Moul JW, Sesterhenn IA.

Prostate. 1997 Jun 15;32(1):59-64.

PMID:
9207958
34.

Incidence and clinical significance of high-grade prostatic intraepithelial neoplasia in TURP specimens.

Gaudin PB, Sesterhenn IA, Wojno KJ, Mostofi FK, Epstein JI.

Urology. 1997 Apr;49(4):558-63.

PMID:
9111625
35.

The role of retroperitoneal lymphadenectomy in mature teratoma of the testis.

Heidenreich A, Moul JW, McLeod DG, Mostofi FK, Engelmann UH.

J Urol. 1997 Jan;157(1):160-3.

PMID:
8976241
36.
37.

Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy.

Bettencourt MC, Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Moul JW.

J Urol. 1996 Sep;156(3):1064-8.

PMID:
8709308
38.

Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer.

Moul JW, Bettencourt MC, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Bauer JJ.

Surgery. 1996 Aug;120(2):159-66; discussion 166-7.

PMID:
8751578
39.

Staging and reporting of prostate cancer--sampling of the radical prostatectomy specimen.

Sakr WA, Wheeler TM, Blute M, Bodo M, Calle-Rodrigue R, Henson DE, Mostofi FK, Seiffert J, Wojno K, Zincke H.

Cancer. 1996 Jul 15;78(2):366-8. No abstract available.

PMID:
8674019
40.

Tumours of the testis and accessory male sex glands.

Ribas JL, Mostofi FK.

IARC Sci Publ. 1996;(126):261-80. Review. No abstract available.

PMID:
8875271
41.

The results of a five-year early prostate cancer detection intervention. Investigators of the American Cancer Society National Prostate Cancer Detection Project.

Mettlin C, Murphy GP, Babaian RJ, Chesley A, Kane RA, Littrup PJ, Mostofi FK, Ray PS, Shanberg AM, Toi A.

Cancer. 1996 Jan 1;77(1):150-9.

PMID:
8630923
42.

Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men.

Moul JW, Sesterhenn IA, Connelly RR, Douglas T, Srivastava S, Mostofi FK, McLeod DG.

JAMA. 1995 Oct 25;274(16):1277-81.

PMID:
7563532
43.

Metanephric adenoma. Clinicopathological study of fifty patients.

Davis CJ Jr, Barton JH, Sesterhenn IA, Mostofi FK.

Am J Surg Pathol. 1995 Oct;19(10):1101-14.

PMID:
7573669
44.

Pathology review in an early prostate cancer detection program: results from the American Cancer Society-National Prostate Cancer Detection Project.

Mostofi FK, Murphy GP, Mettlin C, Sesterhenn IA, Batsakis JG, Khaliq SU, Nadimpalli V, Tahan S, Siders DB, Kollin J, et al.

Prostate. 1995 Jul;27(1):7-12.

PMID:
7541531
45.

Renal medullary carcinoma. The seventh sickle cell nephropathy.

Davis CJ Jr, Mostofi FK, Sesterhenn IA.

Am J Surg Pathol. 1995 Jan;19(1):1-11.

PMID:
7528470
46.

Characteristics of prostate cancer detected in the American Cancer Society-National Prostate Cancer Detection Project.

Mettlin C, Murphy GP, Lee F, Littrup PJ, Chesley A, Babaian R, Badalament R, Kane RA, Mostofi FK.

J Urol. 1994 Nov;152(5 Pt 2):1737-40.

PMID:
7523721
47.

Proliferating cell nuclear antigen expression to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors.

Fernandez EB, Sesterhenn IA, McCarthy WF, Mostofi FK, Moul JW.

J Urol. 1994 Oct;152(4):1133-8.

PMID:
7915335
48.

Clinically detected carcinoma of the prostate treated by radical prostatectomy in a 29-year-old man.

Heidenberg HB, Moul JW, Mostofi FK, McLeod DG.

J Urol. 1994 Sep;152(3):966-7.

PMID:
8051769
50.

Tumours of the testis.

Mostofi FK, Davis J Jr, Rehm S.

IARC Sci Publ. 1994;(111):407-29. Review. No abstract available.

PMID:
8082915

Supplemental Content

Loading ...
Support Center